Provided By GlobeNewswire
Last update: Nov 4, 2024
— Q3 2024 ORLADEYO net revenue of $116.3 million (+35.7 percent y-o-y) —
— Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million (top end of prior guidance range) —
BIOCRYST PHARMACEUTICALS INC
NASDAQ:BCRX (2/21/2025, 8:02:57 PM)
9.21
-0.18 (-1.92%)
Find more stocks in the Stock Screener